Liaoyuan City's first science and technology association organization for non-public enterprises is established within the company.

017 On August 30, Liaoyuan City's first science and technology association organized by a non-public enterprise was established within the company. Ma Xiujun, Chairman of the City Science and Technology Association, along with Li Xiuwu, Deputy Director of the City United Front Work Department and Party Secretary of the City Federation of Industry and Commerce, attended the founding ceremony and delivered important speeches.

The Science and Technology Association of Jilin Boda Weiye Pharmaceutical Co., Ltd. is a mass organization voluntarily formed by the company’s science and technology professionals. It serves as a vital bridge and link between the company’s Party organization and its senior management, playing a key role in driving technological progress and innovation within the company.

Since its establishment, Jilin Province Boda Weiye Pharmaceutical Co., Ltd. has consistently upheld the mission of respecting life and safeguarding human health. Guided by the core values of embracing the finest scientific and technological advancements to build a century-old legacy, the company relies on two cutting-edge R&D platforms—biopharmaceuticals and chemical drugs. As the chairman unit of the Jilin Province Chemical Drug Industry Technology Innovation Strategic Alliance and the Jilin Province Chemical Drug Pilot Testing Center, Boda Weiye is dedicated to the comprehensive development, production, and distribution of biochemical and biopharmaceutical products, with a particular focus on cardiovascular, digestive, anti-cancer, and neuropsychiatric drug categories.

The company boasts an active pharmaceutical ingredient (API) production line capable of manufacturing 3,500 tons annually, equipped with advanced imported and domestically sourced equipment compliant with the latest GMP standards. It also operates a biopharmaceutical production line with an annual capacity of 50 million vials, a large-volume parenteral solutions line producing 20 million vials per year, a small-volume injectable products line churning out 80 million vials annually, and a solid dosage form production line generating 3 billion tablets each year. Since its launch on the market, the company’s independently developed, next-generation Class III national new drug for treating gastric ulcers—Polypruzine Zinc—has earned widespread recognition from clinicians and specialized experts, as well as strong endorsement and popularity among patients suffering from stomach-related ailments. In 2012, this product was honored as one of China’s Top 10 Best-Selling Prescription Drugs at the 68th National Pharmaceutical Fair. Additionally, after review by the Jilin Province Famous Brand Product Promotion Committee, it was officially recognized as a renowned brand product of Jilin Province. Furthermore, in collaboration with Beijing Northland Biotechnology Co., Ltd., the company has jointly developed a Class I national biologic new drug—Recombinant Human Interleukin-11—a groundbreaking biopharmaceutical designed specifically to address thrombocytopenia caused by radiation or chemotherapy in cancer patients. This innovative drug has secured both global and Chinese patents for its unique molecular structure, marking a revolutionary advancement in the field of oncology treatment worldwide.

Currently, the company has 15 product varieties that have successfully transitioned from technological innovation to industrialized production, with 16 additional varieties pending approval from the National Medical Products Administration. Additionally, the company is actively developing 6 more product candidates. Overall, the company has established a strategic framework that balances current production, ongoing research and development, and future innovation—producing one generation while simultaneously preparing the next and continuously advancing cutting-edge R&D efforts.